The regenerative medicine market has experienced rapid expansion; however, regulatory oversight has not consistently kept pace. Licensed clinicians now confront a saturated landscape of suppliers offering exosomes and mesenchymal stem cells (MSCs), with claims that vary from unsubstantiated to actively misleading. Making an informed sourcing decision is a professional obligation with direct implications for patient safety, practice liability, and regulatory compliance.
This article delineates the fundamental compliance indicators that every clinician should identify, along with pertinent questions to be posed before procuring stem cell or exosome products for clinical use.
The Regulatory Baseline: What You Need to Know
Before assessing any supplier, clinicians must understand the fundamental regulatory framework governing stem cell and exosome products in the United States.
There are currently no FDA-approved exosome products for any therapeutic indication [1]. None. Any supplier asserting “FDA-approved exosomes” is making a clearly misleading claim and should be disqualified immediately [2]. Likewise, umbilical cord tissue-derived MSCs are regulated under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products (HCT/Ps), rather than as approved pharmaceuticals [3].
The appropriate federal regulatory framework for these products is cGTP (Current Good Tissue Practice) under 21 CFR Part 1271, rather than cGMP (which pertains to pharmaceutical drugs) [4]. A supplier who confuses these two regulatory categories either misunderstands the law or intends to misrepresent it. Neither scenario is acceptable [5].
Florida Stem Cell Law (SB 1768): A State-Level Compliance Framework
Effective July 1, 2025, Florida Senate Bill 1768, codified as Sections 458.3245 and 459.0127 of the Florida Statutes, grants authority to licensed MDs and DOs to administer non-FDA-approved stem cell therapies for orthopedics, wound care, or pain management, provided specific conditions are met [6][7]. The legislation explicitly forbids the use of stem cells derived from aborted fetuses and sets forth stringent standards for cell sourcing, manufacturing, storage, and documentation [8][9].
Key requirements under SB 1768 include:
- Facility registration and accreditation. Stem cells must be collected, processed, and preserved within an FDA-registered facility that is also licensed or registered with a reputable organization such as the American Association of Tissue Banks (AATB), the Association for the Advancement of Blood and Biotherapies (AABB), or the National Marrow Donor Program (NMDP) [10].
- Cleanroom manufacturing. Cells must be manufactured within an FDA-certified cleanroom environment utilizing HEPA or ULPA filtration to mitigate particulate contamination [11].
- Post-thaw viability documentation. Each product lot must include a post-thaw viability analysis report to verify that the cells remain viable before patient administration [12].
- Informed consent and advertising notices. Physicians are required to obtain written informed consent from each patient and to include a specific statutory notice in all advertisements [13].
For multi-state practices, AATB accreditation is particularly important, as Florida’s statute explicitly designates AATB as an acceptable accrediting body [14]. Furthermore, numerous states that incorporate tissue bank standards within their regenerative medicine regulations also acknowledge AATB accreditation as a primary indicator of quality [15].
AATB Accreditation: The Voluntary Gold Standard
The accreditation provided by the American Association of Tissue Banks (AATB) represents a stringent voluntary quality standard that surpasses the basic regulatory requirements set forth by the FDA [16]. AATB has established extensive standards governing donor screening processes, tissue processing procedures, packaging, labeling, storage protocols, and distribution mechanisms. Facilities that achieve accreditation are subject to regular independent inspections to demonstrate continuous compliance with these standards [17].
In the current biologics market, AATB accreditation, FDA tissue establishment registration, cGTP compliance, and lot-specific Certificates of Analysis serve as credible indicators of quality. Suppliers lacking documentation of these credentials should be approached with utmost caution [18].
cGMP and cGTP for Exosome Manufacturing
Although the HCT/P regulatory framework is founded on cGTP, certain suppliers market exosomes as “cGMP-grade.” A 2025 review in the journal Biology indicates that, owing to the lack of established standards in the field, it is essential to verify that cGMP-grade extracellular vesicles comply with FDA standards for identity, reproducibility, sterility, safety, purity, and potency [19].
Validating each manufacturing step and maintaining batch-to-batch consistency are imperative. An automated bioreactor within a closed system can serve as a valuable instrument for producing cGMP-grade exosomes in a manner that is scalable, cost-effective, and reproducible [20].
Clinicians are advised to inquire with suppliers, “Is your facility registered with the FDA as a tissue establishment? Are your products processed in accordance with cGTP (21 CFR Part 1271) standards? Could you provide a Certificate of Analysis for each lot?”
Nine Red Flags to Avoid
According to prevailing industry guidelines, the following indicators should prompt the prompt disqualification of a supplier [21].
- Claims of “FDA-approved” exosomes or MSCs: No such product exists.
- Misuse of “cGMP” for tissue-based products: The correct framework is cGTP.
- No AATB accreditation: For injectable HCT/Ps, this is a foundational quality signal.
- No lot-specific Certificates of Analysis: Batch documentation must be available.
- No FDA establishment registration: Tissue establishments must be registered.
- No Physical Lab you can visit: Request a laboratory tour to observe the manufacturing process of your product, gain insights into the commitment to quality, purity, and regulatory compliance.
- IND Studies: Inquire about any Investigational New Drug Studies undertaken by the distributor or laboratory supplier; this will demonstrate their commitment to the long-term regulatory approval process.
- No donor eligibility documentation: Screening per 21 CFR Part 1271 Subpart C is required.
- Endotoxin, sterility, or mycoplasma testing not reported: These are mandatory quality controls.
RegenOMedix: Compliant Sourcing for Regenerative Medicine
RegenOMedix acquires stem cell and exosome products manufactured in FDA-registered facilities. These sterile cleanroom environments comply with current Good Manufacturing Practices (cGMP) and are accredited by organizations recognized under Florida statute, such as the American Association of Tissue Banks (AATB) [22]. All products are accompanied by the requisite clinical documentation and compliance credentials required for licensed medical practice. RegenOMedix is actively recruiting practitioners for a sanctioned IRB (Institutional Review Board) study to assess safety, efficacy, and comorbidity in pain, orthopedic, or wound-healing indications treated with its Ascellos Exosomes.
Disclaimer: This content is intended solely for educational and informational purposes. Presently, there are no exosome products approved by the FDA in the United States. These statements are derived from published guidelines and do not constitute legal advice or therapeutic endorsements. Healthcare professionals should seek counsel from qualified legal and regulatory experts for guidance pertinent to their respective practices.
References
[1] “Topical Cosmetic Exosome Biologics for Medspas | Licensed Professionals,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/pages/exosome-biologics-for-medspas
[2] “Exosome Biologics & UCT-MSC Stem Cells for Licensed Professionals,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/
[3] “FDA Warns About Stem Cell Therapies,” U.S. Food and Drug Administration (FDA). [Online]. Available: https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
[4] “Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps),” U.S. Food and Drug Administration (FDA), Aug. 2023. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
[5] “Florida Stem Cell Law Updates and Insights,” RegenOMedix, Jun. 2025. [Online]. Available: https://regenomedix.com/florida-stem-cell-law/
[6] “Senate Bill 1768 (2025) – The Florida Senate,” Florida Senate, 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768
[7] “SB 1768 — Stem Cell Therapy – 2025 Bill Summaries,” Florida Senate, 2025. [Online]. Available: https://www.flsenate.gov/Committees/billsummaries/2025/html/1768
[8] “Florida Senate Bill 1768 – Amendments and Actions,” Florida Senate, 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768
[9] “Stem Cell Therapy – Chapter No. 2025-185 (SB 1768),” Florida Senate, Jun. 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768
[10] “FDA Warning Letters on Exosome Products: Regulatory Classification, Enforcement Trends, and Criminal Risks,” Armstrong Brady Lyons, Apr. 2026. [Online]. Available: https://www.armstrongbradylyons.com/library/fda-warning-letters-exosome-product
[11] “Regulating Human Tissue Banks,” STU Scholarly Works, Jun. 2006. [Online]. Available: https://scholarship.stu.edu/cgi/viewcontent.cgi?article=1284&context=stlr
[12] “GTP vs GMP for HCT/Ps: Guide to FDA Tissue Regulations,” FDAMap. [Online]. Available: https://www.fdamap.com/valuable-insights/navigating-gtp-and-gmp-for-human-cells-and-tissue-products-hct-ps.html
[13] “Selecting the Right Biomaterial Product: Regulatory Considerations and Terminology,” Versiti Clinical Trials. [Online]. Available: https://versiticlinicaltrials.org/resources/insights/selecting-the-right-biomaterial-product
[14] “Accreditation Standards,” Parents’ Guide to Cord Blood Foundation. [Online]. Available: https://parentsguidecordblood.org/en/accreditation
[15] “Association for Advancing Tissue and Biologics (AATB) | Institutional Accreditation,” AATB. [Online]. Available: https://www.aatb.org/
[16] “LifeCell Receives Accreditation From American Association of Tissue Banks (AATB),” PR Newswire, Jan. 2020. [Online]. Available: https://www.prnewswire.com/in/news-releases/lifecell-receives-accreditation-from-american-association-of-tissue-banks-aatb–807254272.html
[17] “Manufacturing – AATB Accredited, FDA-Registered, cGMP-Compliant,” BioStem Technologies. [Online]. Available: https://biostemtechnologies.com/manufacturing/
[18] “FDA Birth Tissue Industry Guidance | AATB Standards for Tissue Banking,” Birth Tissue Recovery. [Online]. Available: https://birthtissuerecovery.com/industry-partners/
[19] E. F. Wiest and A. C. Zubair, “Generation of Current Good Manufacturing Practices-Grade Mesenchymal Stromal Cell-Derived Extracellular Vesicles Using Automated Bioreactors,” Biology, vol. 14, no. 3, p. 313, Mar. 2025. doi: 10.3390/biology14030313. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/40136569/
[20] “Current Good Manufacturing Practice Requirements for Combination Products – FDA,” U.S. Food and Drug Administration (FDA). [Online]. Available: https://www.fda.gov/media/90425/download
[21] “Kimera Labs, Inc. – Warning Letter,” U.S. Food and Drug Administration (FDA), Sep. 2023. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kimera-labs-inc-649343-09012023
[22] “A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19,” ClinicalTrials.gov, NCT05787288. [Online]. Available: https://clinicaltrials.gov/study/NCT05787288
